Skip to main content
Caplight Logo









Human Biome S.A.

Human Biome S.A.

Private
WarsawHealthcare & Life Scienceshttps://human-biome.com/en/

Last Round

Series A

Mar 1, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Human Biome S.A. is a biotechnology company that develops New-Generation Biotherapeutics (NGB) and Fecal Microbiota Transplantation (FMT) preparations to treat chronic diseases and combat antimicrobial resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

microbiome therapeuticsFecal Microbiota TransplantationFMTpoop transplantC. diff treatmentNew-Generation BiotherapeuticsNGBlive biotherapeutic productsAI drug discoveryantimicrobial resistanceAMRmicrobiota bankingbiosynthetic microbiome therapiesdonor-independent therapiesin-silico drug discoverygraft-versus-host diseaseGvHDGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Human Biome S.A. Comparables

Compare Human Biome S.A. with similar companies based on industry and business-model similarity.

Human Biome S.A. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mikrobiomik
88%
BiomeBank
83%
EnteroBiotix
82%

Human Biome S.A. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 1, 2026

Key People

Founding team and executive leadership

Jarosław Biliński

CEO

Executive Team

Human Biome S.A. Investors

Notable investors and investment history

Human Biome S.A. investors
InvestorRounds
COBIN AngelsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 56% MoM.

  • Apr 10, 2026

    Grew 17% QoQ, from 24 to 28 employees.

Human Biome S.A. Filings

Explore SEC and related filing metadata, where available.

Human Biome S.A. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Human Biome S.A.'s valuation, stock price, and market status.

Is Human Biome S.A. a public or private company?

Human Biome S.A. is a private company.

What is the current stock price of Human Biome S.A.?

Human Biome S.A. is a private company with no public stock price. No recent secondary market data is available.

How much is Human Biome S.A. worth (valuation)?

Valuation information for Human Biome S.A. is not publicly available.

Can I buy Human Biome S.A. stock?

Human Biome S.A. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Human Biome S.A.'s last funding round?

Funding round information for Human Biome S.A. is not publicly available.

Who are the main investors in Human Biome S.A.?

Investor information for Human Biome S.A. is not publicly disclosed.

Will Human Biome S.A. IPO soon?

No public IPO plans have been announced for Human Biome S.A..

How can I track Human Biome S.A. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Human Biome S.A.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWarsaw
Employee Range20
Year Founded2014
Last FundingMar 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?